Dysmenorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Jan. 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Dysmenorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2018http://www.reportlinker.com/p0648877/Dysmenorrhea-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Dysmenorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2018
SummaryGlobalData estimates that the global dysmenorrhea therapeutics market was valued at $4.1 billion in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% over the next eight years to reach $4.8 billion by 2018. This low value growth in the dysmenorrhea therapeutics market is primarily attributed to the high usage of low priced OTC (Over-The-Counter) and off-label drugs and the low penetration of the patented product Celebrex (celecoxib). However, an increase in the patient population will be the primary contributor to the growth of the market in the forecast period.
Scope
The report provides information on the key drivers and challenges of the dysmenorrhea market. Its scope includes - - Annualized global dysmenorrhea market revenues data from 2005 to 2010, forecast for eight years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as low dose estrogen-progesterone, NSAID, vasopressin antagonist, cytochrome inhibitor, phosphodiesterase inhibitor, sodium channel blockers and prostaglandin inhibitors.- Analysis of the current and future competition in the global dysmenorrhea therapeutics market. Key market players covered are Nobelpharma and Vantia Therapeutics. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the dysmenorrhea therapeutics market.- Analysis of key recent licensing and partnership agreements in dysmenorrhea therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global dysmenorrhea therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global dysmenorrhea therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What's the next big thing in the global dysmenorrhea therapeutics market landscape? – Identify, understand and capitalize.
Table of Contents1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Dysmenorrhea Therapeutics: Introduction 7
2.1 Disease Overview 7
2.1.1 Primary Dysmenorrhea 7
2.1.2 Secondary Dysmenorrhea 7
2.2 Epidemiology 7
2.2.1 Prevalence 7
2.2.2 Quality of Life 8
2.2.3 Pharma-economic Burden 8
2.3 Etiology and Pathophysiology 9
2.4 Signs and Symptoms 10
2.5 Diagnosis 11
2.5.1 Clinical Approach 11
2.5.2 Physical Examination 11
2.5.3 Investigational Approach 11
2.6 Treatment and Management Options 12
2.6.1 Non Pharmacological Treatment 12
2.6.2 Pharmacological Treatment 12
2.7 Referral Pathway 13
2.8 GlobalData Pipeline Report Guidance 14
3 DysmenorrheaTherapeutics: Market Characterization 15
3.1 Overview 15
3.2 Dysmenorrhea Therapeutics Market Size (2005-2010) – Global 15
3.3 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – Global 16
3.4 Dysmenorrhea Therapeutics Market Size (2005-2010) – The US 17
3.5 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – The US 18
3.6 Dysmenorrhea Therapeutics Market Size (2005-2010) – France 19
3.7 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – France 20
3.8 Dysmenorrhea Therapeutics Market Size (2005-2010) – Germany 21
3.9 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – Germany 22
3.10 Dysmenorrhea Therapeutics Market Size (2005-2010) – Italy 23
3.11 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – Italy 24
3.12 Dysmenorrhea Therapeutics Market Size (2005-2010) – Spain 25
3.13 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – Spain 26
3.14 Dysmenorrhea Therapeutics Market Size (2005-2010) – The UK 27
3.15 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – The UK 28
3.16 Dysmenorrhea Therapeutics Market Size (2005-2010) – Japan 29
3.17 Dysmenorrhea Therapeutics Market Forecast (2010-2018) – Japan 30
3.18 Drivers and Barriers for the Dysmenorrhea Therapeutics Market 31
3.18.1 Drivers for the Dysmenorrhea Therapeutics Market 31
3.18.2 Barriers for the Dysmenorrhea Therapeutics Market 31
3.19 Opportunity and Unmet Need Analysis 31
3.20 Key Takeaway 32
4 Dysmenorrhea Therapeutics: Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profiles for the Major Marketed Products in the Dysmenorrhea Therapeutics Market 34
4.3.1 Diclofenac Potassium 34
4.3.2 Celebrex (Celecoxib) 35
4.3.3 Naproxen Sodium 36
4.4 Key Takeaway 37
5 Dysmenorrhea Therapeutics: Pipeline Assessment 38
5.1 Overview 38
5.2 Strategic Pipeline Assessment 38
5.3 Dysmenorrhea Therapeutics Pipeline – Pipeline by Phases of Development 38
5.3.1 Dysmenorrhea Therapeutics – Phase III Pipeline 38
5.3.2 Dysmenorrhea Therapeutics – Phase II Pipeline 39
5.3.3 Dysmenorrhea Therapeutics – Phase I Pipeline 39
5.3.4 Dysmenorrhea Therapeutics – Pre-Clinical Pipeline 39
5.3.5 Technology Trends Analytic Framework 40
5.4 Dysmenorrhea Therapeutics Market – Pipeline by Mechanism of Action 42
5.5 Molecule Profile for Promising Drugs under Clinical Development 43
5.5.1 NPC-01 43
5.5.2 VA111913 TS 44
5.6 Key Takeaway 44
6 Dysmenorrhea Therapeutics: Clinical Trials Mapping 45
6.1 Clinical Trials by Region/Country (The US, the EU and Japan) 45
6.2 Clinical Trials by Phase 46
6.3 Clinical Trials by Trial Status 47
6.4 Prominent Sponsors 48
6.5 Top Companies Participating in Dysmenorrhea Therapeutics Clinical Trials 50
7 Strategic Assessment 51
7.1 Key Events Impacting the Future Market 51
7.2 Dysmenorrhea Therapeutics: Implications for Future Market Competition 52
8 Dysmenorrhea Therapeutics: Future Players 53
8.1 Introduction 53
8.2 Company Profiles 54
8.2.1 Nobelpharma Co., Ltd 54
8.2.2 Vantia Therapeutics 55
9 Dysmenorrhea Therapeutics: Appendix 56
9.1 Market Definitions 56
9.2 Abbreviations 56
9.3 Methodology 57
9.3.1 Coverage 57
9.3.2 Secondary Research 58
9.3.3 Forecasting 58
9.3.4 Primary Research 59
9.3.5 Expert Panel Validation 60
9.4 Contact Us 60
9.5 Disclaimer 60
9.6 Bibliography 60
List of TablesTable 1: Dysmenorrhea Therapeutics Market, Global, Revenue ($m), 2005-2010 15
Table 2: Dysmenorrhea Therapeutics Market, Global, Forecast ($m), 2010-2018 16
Table 3: Dysmenorrhea Therapeutics Market, The US, Revenue ($m), 2005-2010 17
Table 4: Dysmenorrhea Therapeutics Market, The US, Forecasts ($m), 2010-2018 18
Table 5: Dysmenorrhea Therapeutics Market, France, Revenue ($m), 2005–2010 19
Table 6: Dysmenorrhea Therapeutics Market, France, Forecasts ($m), 2010-2018 20
Table 7: Dysmenorrhea Therapeutics Market, Germany, Revenue ($m), 2005-2010 21
Table 8: Dysmenorrhea Therapeutics Market, Germany, Forecasts ($m), 2010-2018 22
Table 9: Dysmenorrhea Therapeutics Market, Italy, Revenue ($m), 2005-2010 23
Table 10: Dysmenorrhea Therapeutics Market, Italy, Forecasts ($m), 2010-2018 24
Table 11: Dysmenorrhea Therapeutics Market, Spain, Revenue ($m), 2005-2010 25
Table 12: Dysmenorrhea Therapeutics Market, Spain, Forecasts ($m), 2010-2018 26
Table 13: Dysmenorrhea Therapeutics Market, The UK, Revenue ($m), 2005-2010 27
Table 14: Dysmenorrhea Therapeutics Market, The UK, Forecasts ($m), 2010-2018 28
Table 15: Dysmenorrhea Therapeutics Market, Japan, Revenue ($m), 2005-2010 29
Table 16: Dysmenorrhea Therapeutics Market, Japan, Forecasts ($m), 2010-2018 30
Table 17: Mean TOTPAR-8 and SPID-8 values for Celebrex, Naproxen Sodium and Placebo 35
Table 18: Dysmenorrhea Therapeutics – Phase III Pipeline, 2011 38
Table 19: Dysmenorrhea Therapeutics – Phase II Pipeline, 2011 39
Table 20: Dysmenorrhea Therapeutics – Phase I Pipeline, 2011 39
Table 21: Dysmenorrhea Therapeutics – Pre-Clinical Pipeline, 2011 39
Table 22: Dysmenorrhea Therapeutics – Clinical Trials by Country, 2011 45
Table 23: Dysmenorrhea Therapeutics - Clinical Trials by Phase, 2011 46
Table 24: Dysmenorrhea Therapeutics - Clinical Trials by Status, 2010 47
Table 25: Dysmenorrhea Therapeutics - Prominent Sponsors, 2011 49
Table 26: Dysmenorrhea Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 50
Table 27: Nobelpharma – Pipeline, 2011 54
Table 28: Vantia Therapeutics – Pipeline, 2011 55
List of FiguresFigure 1: Etiology of Dysmenorrhea 9
Figure 2: Pathophysiology of Primary Dysmenorrhea 10
Figure 3: Treatment Pattern of Primary Dysmenorrhea 13
Figure 4: Referral Pathway for Dysmenorrhea 13
Figure 5: Dysmenorrhea Therapeutics Market, Global, Revenue ($m), 2005-2010 15
Figure 6: Dysmenorrhea Therapeutics Market, Global, Forecast ($m), 2010-2018 16
Figure 7: Dysmenorrhea Therapeutics Market, the US, Revenue ($m), 2005-2010 17
Figure 8: Dysmenorrhea Therapeutics Market, The US, Forecast ($m), 2010-2018 18
Figure 9: Dysmenorrhea Therapeutics Market, France, Revenue ($m), 2005-2010 19
Figure 10: Dysmenorrhea Therapeutics Market, France, Forecast ($m), 2010-2018 20
Figure 11: Dysmenorrhea Therapeutics Market, Germany, Revenue ($m), 2005-2010 21
Figure 12: Dysmenorrhea Therapeutics Market, Germany, Forecast ($m), 2010-2018 22
Figure 13: Dysmenorrhea Therapeutics Market, Italy, Revenue ($m), 2005-2010 23
Figure 14: Dysmenorrhea Therapeutics Market, Italy, Forecast ($m), 2010-2018 24
Figure 15: Dysmenorrhea Therapeutics Market, Spain, Revenue ($m), 2005-2010 25
Figure 16: Dysmenorrhea Therapeutics Market, Spain, Forecast ($m), 2010-2018 26
Figure 17: Dysmenorrhea Therapeutics Market, The UK, Revenue ($m), 2005-2010 27
Figure 18: Dysmenorrhea Therapeutics Market, The UK, Forecast ($m), 2010-2018 28
Figure 19: Dysmenorrhea Therapeutics Market, Japan, Revenue ($m), 2005-2010 29
Figure 20: Dysmenorrhea Therapeutics Market, Japan, Forecast ($m), 2010-2018 30
Figure 21: Opportunity and Unmet Need in the Dysmenorrhea Therapeutics Market 32
Figure 22: Dysmenorrhea Therapeutics – Strategic Competitor Assessment, 2011 33
Figure 23: Dysmenorrhea Therapeutics – Pipeline by Phase of Development, 2011 38
Figure 24: Dysmenorrhea Therapeutics – Technology Trends Analytics Framework, 2011 40
Figure 25: Dysmenorrhea Therapeutics – Technology Trends Analytics Framework – Description, 2011 41
Figure 26: Dysmenorrhea Therapeutics – Pipeline by Mechanism of Action, 2011 42
Figure 27: Clinical Trial Details of NPC-01 43
Figure 28: Clinical Trial Details of VA111913 TS 44
Figure 29: Dysmenorrhea Therapeutics – Clinical Trials by Country, 2011 45
Figure 30: Dysmenorrhea Therapeutics - Clinical Trials by Phase, 2011 46
Figure 31: Dysmenorrhea Therapeutics - Clinical Trials by Status, 2011 47
Figure 32: Dysmenorrhea Therapeutics - Overall Sponsors, 2011 48
Figure 33: Dysmenorrhea Therapeutics - Prominent Sponsors, 2011 49
Figure 34: Dysmenorrhea Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 50
Figure 35: Dysmenorrhea Therapeutics Market, Drivers and Restraints 2011 51
Figure 36: Implications for Future Market Competition in the Dysmenorrhea Market, 2011 52
Figure 37: Dysmenorrhea Therapeutics Market – Pipeline by Company, 2011 53
Companies MentionedVantia Therapeutics
To order this report:Therapy Industry: Dysmenorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2018More
Market Research ReportCheck our
Industry Analysis and InsightsNicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article